MetLife, Inc. (MET) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MET SEC filings page.
MetLife, Inc. (MET) reported $79.4B in revenue over the twelve months to Jun 30, 2026, up 8.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MetLife’s numbers describe a balance-sheet-intensive insurer where strong reported cash generation coexists with rising leverage and modest operating-margin pressure.
In FY2025, operating cash flow was$17.1B against net income of$3.2B , a gap that makes earnings look less representative of reported cash movement. Yet debt-to-equity rose to 25.2x from 23.7x in FY2024, indicating that cash generation did not translate into a simpler capital structure.
Debt-to-equity reached 25.2x in FY2025, up from 21.9x in FY2023, so a relatively small equity base supports a much larger liability structure. Liabilities were
Revenue reached
Financial Health Signals
Scored against insurers for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of MetLife, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Loss Ratio measures the claims an insurer paid out against the premiums it earned, so a lower ratio leaves more of every premium dollar with the company. MetLife, Inc. scores 8/100 on it among other insurers.
Not available for MetLife, Inc., and counted as zero in the overall score.
MetLife, Inc. funded 3.8% of its assets with shareholders' equity at the end of fiscal year 2025, holding $28.4B of equity against $745.2B of assets. Capital ranks insurers on that cushion, and MetLife, Inc. scores 10/100 among other insurers.
Not available for MetLife, Inc., and counted as zero in the overall score.
Combined Ratio puts claims and running costs together against premiums earned, and a figure under 100% means the underwriting made money before any investment income was counted. MetLife, Inc. scores 22/100 on it among other insurers.
MetLife, Inc. reported net income of $3.2B in fiscal year 2025, against $4.2B in fiscal year 2024. Stability ranks insurers on how steady net income has been across five years, and MetLife, Inc. scores 63/100 among other insurers.
MetLife, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, MetLife, Inc. generates $5.39 in operating cash flow ($17.1B OCF vs $3.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
MetLife, Inc. earns $8.48 in operating income for every $1 of interest expense ($6.1B vs $724.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
MetLife, Inc. generated $19.2B in revenue in Q2 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.
MetLife, Inc.'s EBITDA was $1.6B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.7% from the same quarter a year earlier. Against the prior quarter it is down 1.0%.
MetLife, Inc. reported $736.0M in net income in Q2 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is down 37.9%.
MetLife, Inc. earned $1.09 per diluted share (EPS) in Q2 2026. This represents an increase of 5.8% from the same quarter a year earlier. Against the prior quarter it is down 37.4%.
Cash & Balance Sheet
MetLife, Inc. held $19.3B in cash as of Q2 2026; long-term debt is not reported for that period.
MetLife, Inc. paid $0.59 per share in dividends in Q2 2026. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is up 4.4%.
Not reported for Q2 2026.
Margins & Returns
MetLife, Inc.'s operating margin was 8.4% in Q2 2026, reflecting core business profitability. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
MetLife, Inc.'s net profit margin was 3.8% in Q2 2026, showing the share of revenue converted to profit. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.
MetLife, Inc.'s ROE was 2.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
Not reported for Q2 2026.
Capital Allocation
MetLife, Inc. spent $722.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 41.6% from the same quarter a year earlier. Against the prior quarter it is down 4.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
MET Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2B+10.5% | $19.1B+2.7% | $23.8B+27.6% | $17.4B-5.9% | $17.3B-2.7% | $18.6B+15.6% | $18.7B-1.9% | $18.4B+16.2% |
| SG&A Expenses | $154.0M+18.5% | $132.0M+4.8% | $186.0M+933.3% | $118.0M-27.2% | $130.0M-15.0% | $126.0M-14.9% | $18.0M | $162.0M-22.5% |
| Operating Income | $1.6B+15.1% | $1.6B+15.3% | $1.7B+12.6% | $1.6B+14.4% | $1.4B-16.2% | $1.4B+1.0% | $1.5B | $1.4B |
| EBITDA | $1.6B+15.7% | $1.7B+15.0% | $1.8B+11.3% | $1.7B+14.0% | $1.4B-16.0% | $1.4B+1.0% | $1.6B | $1.5B |
| Interest Expense | $292.0M+8.6% | $265.0M+2.7% | -$74.0M-85.0% | $271.0M+5.4% | $269.0M+4.7% | $258.0M-2.3% | -$40.0M | $257.0M-3.0% |
| Income Tax | $256.0M+4.5% | $345.0M-14.6% | $301.0M+184.0% | $308.0M-52.8% | $245.0M-1.6% | $404.0M+137.6% | $106.0M | $653.0M+1574.4% |
| Net Income | $736.0M+1.0% | $1.2B+25.4% | $603.0M-43.7% | $896.0M-33.2% | $729.0M-22.9% | $945.0M+9.0% | $1.1B+76.4% | $1.3B+174.4% |
| EPS (Basic) | $1.10+5.8% | $1.75+35.7% | $1.18-33.7% | $1.23-32.4% | $1.04-18.8% | $1.29+16.2% | $1.78+128.2% | $1.82+225.0% |
| EPS (Diluted) | $1.09+5.8% | $1.74+35.9% | $1.17-33.9% | $1.22-32.6% | $1.03-19.5% | $1.28+16.4% | $1.77+129.9% | $1.81+223.2% |
| Diluted Shares (Avg) | 647M-4.2% | 656M-4.6% | N/A | 669M-4.9% | 675M-5.6% | 687M-5.7% | N/A | 704M-6.9% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
MET Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $759.4B+8.1% | $743.2B+8.0% | $745.2B+10.0% | $719.7B+2.1% | $702.5B+4.0% | $688.3B+1.6% | $677.5B-1.5% | $705.0B+8.1% |
| Cash & Equivalents | $19.3B-13.0% | $22.7B+6.4% | $22.0B+9.8% | $20.2B-7.0% | $22.2B+6.7% | $21.3B+7.5% | $20.1B-2.8% | $21.8B+46.0% |
| Short-Term Investments | $8.0B+51.2% | $4.9B-10.7% | $3.6B-30.2% | $6.0B+29.4% | $5.3B+39.3% | $5.5B+13.5% | $5.2B-14.7% | $4.6B-29.1% |
| Accounts Receivable | $370.0M+39.6% | $393.0M+54.7% | $272.0M+14.3% | $280.0M+14.3% | $265.0M+14.7% | $254.0M+1.2% | $238.0M-2.1% | $245.0M+2.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $9.5B+4.3% | $9.6B+5.9% | $9.6B+8.0% | $9.1B-0.7% | $9.1B+2.1% | $9.0B0.0% | $8.9B-3.6% | $9.2B+0.5% |
| Total Liabilities | $731.4B+8.4% | $715.4B+8.3% | $716.2B+10.2% | $690.5B+2.5% | $674.5B+4.1% | $660.6B+1.8% | $649.8B-1.2% | $673.8B+7.6% |
| Total Equity | $27.4B-0.9% | $27.3B-0.6% | $28.4B+3.5% | $28.9B-6.3% | $27.7B+1.6% | $27.5B-3.7% | $27.4B-8.6% | $30.9B+20.4% |
| Retained Earnings | $45.4B+4.4% | $45.1B+4.5% | $44.3B+3.9% | $43.9B+5.1% | $43.4B+6.3% | $43.1B+6.9% | $42.6B+6.2% | $41.8B+4.5% |
Not reported in any period shown, so not listed: Current Assets, Inventory, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
MET Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.2B+1.9% | $2.7B-37.0% | $7.1B+53.5% | $3.6B-14.4% | $2.2B-37.3% | $4.3B+83.1% | $4.6B-11.0% | $4.2B+20.0% |
| Depreciation & Amortization | $40.0M+42.9% | $29.0M0.0% | $30.0M-9.1% | $30.0M-6.3% | $28.0M-3.4% | $29.0M0.0% | $33.0M+17.9% | $32.0M+23.1% |
| Investing Cash Flow | -$8.9B-197.6% | -$5.5B-64.2% | -$4.3B+20.1% | -$5.0B-132.1% | -$3.0B-122.5% | -$3.3B-26.5% | -$5.4B-1031.3% | -$2.2B+27.3% |
| Financing Cash Flow | $3.2B+121.9% | $3.6B+1517.7% | -$998.0M-92.3% | -$508.0M+55.7% | $1.4B+220.2% | $220.0M+184.3% | -$519.0M-194.9% | -$1.1B-35.1% |
| Dividends Paid | $383.0M+0.3% | $372.0M-0.5% | $375.0M-0.8% | $378.0M-1.3% | $382.0M-1.8% | $374.0M-0.8% | $378.0M-2.1% | $383.0M-2.3% |
| Share Buybacks | $722.0M+41.6% | $755.0M-46.5% | $460.0M+13.3% | $502.0M-35.1% | $510.0M-40.4% | $1.4B+20.4% | $406.0M-52.7% | $774.0M-2.3% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow.
MET Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 8.4%+0.3pp | 8.6%+0.9pp | 7.0%-0.9pp | 9.5%+1.7pp | 8.0%-1.3pp | 7.6%-1.1pp | 8.0% | 7.8% |
| Net Margin | 3.8%-0.4pp | 6.2%+1.1pp | 2.5%-3.2pp | 5.2%-2.1pp | 4.2%-1.1pp | 5.1%-0.3pp | 5.7%+2.6pp | 7.3%+4.2pp |
| Return on Equity | 2.7%+0.1pp | 4.3%+0.9pp | 2.1%-1.8pp | 3.1%-1.2pp | 2.6%-0.8pp | 3.4%+0.4pp | 3.9%+1.9pp | 4.3%+2.4pp |
| Return on Assets | 0.1%0.0pp | 0.2%0.0pp | 0.1%-0.1pp | 0.1%-0.1pp | 0.1%0.0pp | 0.1%0.0pp | 0.2%+0.1pp | 0.2%+0.1pp |
| Debt-to-Equity | 26.65+2.3x | 26.18+2.2x | 25.22+1.5x | 23.86+2.0x | 24.36+0.6x | 24.03+1.3x | 23.67+1.8x | 21.82-2.6x |
| Asset Turnover | 0.030.0x | 0.030.0x | 0.030.0x | 0.020.0x | 0.020.0x | 0.030.0x | 0.030.0x | 0.030.0x |
Not reported in any period shown, so not listed: Gross Margin, Current Ratio, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MetLife, Inc. MET | FY2025 | $77.1B | $3.2B | 4.1% | $62.5B | 17/100 |
| Aflac Inc. AFL | FY2025 | $17.2B | $3.6B | 21.2% | $57.4B | 48/100 |
| Prudential Financial, Inc. PRU | FY2025 | $60.8B | $3.6B | 5.9% | $39.0B | 11/100 |
| Globe Life Inc. GL | FY2025 | $6.0B | $1.2B | 19.4% | $12.6B | 43/100 |
| Unum Group UNM | FY2025 | $13.1B | $738.5M | 5.7% | $14.5B | 29/100 |
Where MetLife, Inc. Ranks
Frequently Asked Questions
What is MetLife, Inc.'s annual revenue?
MetLife, Inc. (MET) reported $77.1B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is MetLife, Inc.'s revenue growing?
MetLife, Inc. (MET) revenue grew by 8.6% year-over-year, from $71.0B to $77.1B in fiscal year 2025.
Is MetLife, Inc. profitable?
Yes, MetLife, Inc. (MET) reported a net income of $3.2B in fiscal year 2025, with a net profit margin of 4.1%.
What is MetLife, Inc.'s EBITDA?
MetLife, Inc. (MET) had EBITDA of $6.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is MetLife, Inc.'s operating margin?
MetLife, Inc. (MET) had an operating margin of 8.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is MetLife, Inc.'s net profit margin?
MetLife, Inc. (MET) had a net profit margin of 4.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does MetLife, Inc. pay dividends?
Yes, MetLife, Inc. (MET) paid $2.25 per share in dividends during fiscal year 2025.
What is MetLife, Inc.'s return on equity (ROE)?
MetLife, Inc. (MET) has a return on equity of 11.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is MetLife, Inc.'s operating cash flow?
MetLife, Inc. (MET) generated $17.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are MetLife, Inc.'s total assets?
MetLife, Inc. (MET) had $745.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What is MetLife, Inc.'s debt-to-equity ratio?
MetLife, Inc. (MET) had a debt-to-equity ratio of 25.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MetLife, Inc.'s return on assets (ROA)?
MetLife, Inc. (MET) had a return on assets of 0.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is MetLife, Inc.'s P/E ratio?
MetLife, Inc. (MET) trades at 18.3x earnings, its market capitalization divided by net income of $3.4B net income, trailing 12 months to June 30, 2026. The market capitalization is $62.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MetLife, Inc.'s price-to-sales ratio?
MetLife, Inc. (MET) trades at 0.8x sales, its market capitalization divided by revenue of $79.4B revenue, trailing 12 months to June 30, 2026. The market capitalization is $62.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MetLife, Inc.'s Piotroski F-Score?
MetLife, Inc. (MET) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MetLife, Inc.'s earnings high quality?
MetLife, Inc. (MET) has an earnings quality ratio of 5.39x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can MetLife, Inc. cover its interest payments?
MetLife, Inc. (MET) has an interest coverage ratio of 8.48x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is MetLife, Inc.?
MetLife, Inc. (MET) scores 17 out of 100 on our Financial Health Score, indicating weak standing within its insurers peer group. The score is a 0-100 composite of six dimensions (Loss Ratio, Premium Growth, Capital, Investment Yield, Combined Ratio, Stability), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.